Disappointing data lead Pfizer to drop heart drug acquired as part of $11B deal

Retrieved on: 2022-08-04 17:03:45

Tags for this article:

Click the tags to see associated articles and topics

Disappointing data lead Pfizer to drop heart drug acquired as part of $11B deal. View article details on hiswai:

Excerpt

Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed.

Article found on: medcitynews.com